Who Paid My Doc
Ashley Rhodes
Adolescent Medicine Monteagle, TN Medical Doctor
NPI 1962852103 CMS profile 2666163
21 1St St, Monteagle, TN 37356
General payments
$1,089
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Ashley Rhodes of Monteagle, TN is reported in the CMS Open Payments database as having received $1,089 across 61 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $32 | 2 | |
| 2023 | General | $99 | 4 | |
| 2022 | General | $530 | 29 | |
| 2021 | General | $248 | 15 | |
| 2020 | General | $129 | 8 | |
| 2019 | General | $52 | 3 |
Beside peers
- Ashley Rhodes
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Ashley Rhodes were reported at $0. Among 40 Adolescent Medicine profiles paid that year, the median was $135 and the middle half received between $78 and $573.
Show as a table
| Year | Ashley Rhodes | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $52 | $112 | $24–$444 | $163 |
| 2020 | $129 | $80 | $35–$250 | $114 |
| 2021 | $248 | $229 | $55–$448 | $132 |
| 2022 | $530 | $162 | $35–$492 | $149 |
| 2023 | $99 | $182 | $54–$507 | $160 |
| 2024 | $32 | $142 | $59–$362 | $164 |
| 2025 | $0 | $135 | $78–$573 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 62 drugsPart D claims
2,003
Drug cost
$174,273
Branded share of claims
17.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 25 | $42,371 | |
| Ozempic Semaglutide | Brand | 25 | $38,142 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 20 | $25,351 | |
| Jardiance Empagliflozin | Brand | 21 | $20,267 | |
| Farxiga Dapagliflozin Propanediol | Brand | 25 | $17,831 | |
| Xarelto Rivaroxaban | Brand | 16 | $13,631 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 47 | $1,679 | |
| Atorvastatin Calcium | Generic | 178 | $1,367 | |
| Levothyroxine Sodium | Generic | 131 | $1,045 | |
| Gabapentin | Generic | 71 | $906 |
The 10 drugs with the highest cost, of 62 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Records
61 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adolescent Medicine in Tennessee
Related records
Adolescent Medicine in Tennessee
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Tennessee
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.